AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06221072
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg by intravenous drip (100mL:4mg) every 4 weeks
Trial: NCT05467293
Drug: 0.3% YP-P10 Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: YP-P10 Ophthalmic Solution
Trial: NCT05467293
Drug: 1% YP-P10 Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: YP-P10 Ophthalmic Solution
Trial: NCT05467293
Drug: YP-P10 Placebo Ophthalmic Solution (vehicle)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo YP-P10 Placebo Ophthalmic Solution (vehicle)
Trial: NCT04434326
Drug: [14]CM082 suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before administration, the solid powder for administration was placed at room temperature. 40 ml drinking water was added into the drug container to prepare the suspension for the subjects to take. After that, 200 ml drinking water was used to repeatedly rinse the drug container for many times, and the subjects continued to take the lotion. Take care not to spill the liquid out of the bottle when shaking
Trial: NCT05716295
Drug: MDK-703
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDK-703 will be administered as specified under Arm description.
Trial: NCT05716295
Drug: Checkpoint Inhibitor, Immune
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Checkpoint inhibitor will be administered as specified under Arm description.
Trial: NCT04745975
Drug: Personalized treatment guided by mini-PDX and RNA sequencing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized treatment guided by mini-PDX and RNA sequencing
Trial: NCT04745975
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1250 mg/m2 bid po
Trial: NCT04787354
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine: 2,000 mg/m2/day
Trial: NCT05223010
Drug: Melatonin 5 MG/15 ML Oral Solution 0.2mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will be administered 1 hour before arrival to operating room
Trial: NCT05223010
Drug: Melatonin 5 MG/15 ML Oral Solution 0.4mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will be administered 1 hour before arrival to operating room
Trial: NCT05631938
Drug: cytisinicline
RxNorm normalized name: cytisinicline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated oral tablets containing 3 mg cytisinicline
Trial: NCT04577001
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active ingredient taken orally daily for 6 months
Trial: NCT05157243
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two matching placebo tablets administered orally with food twice daily for 5 days
Trial: NCT05427084
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT05155215
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m\^2 per day for 3 days (IV)
Trial: NCT05364619
Drug: Qingre Huashi Granules combined the modified dual therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingre Huashi Granules combined the modified dual therapy for 14 days
Trial: NCT05909826
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg PO days 1 to 21, every 4 weeks
Trial: NCT05672901
Drug: Estrace 0.01% Vaginal Cream
RxNorm normalized name: Estrace 0.01% Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrace is a prescriptive female hormone indicated in the treatment of moderate to severe symptoms of Genitourinary Syndrome of Menopause.
Trial: NCT04840888
Drug: LY3484356
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06376318
Drug: anti-bodies
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-Dipeptidyl peptidase 3 (DPP3), Anti-Bioactive adrenomedullin (bio-ADM)
Trial: NCT04956263
Drug: YG1699
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~The proposed dosage form is a yellow, film-coated tablet for oral administration. The proposed tablet strengths for the current clinical research are 5 mg and 25 mg. The tablets are packaged in high-density polyethylene (HDPE) bottles with HDPE caps and desiccant inserters. Each HDPE bottle contains 30 tablets of drug product.~The study drug YG1699 is manufactured by Youngene Therapeutics Inc., Ltd., China.
Trial: NCT00368342
Drug: Erythromycin, Azithromycin , Clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00317733
Drug: Ketoprofen in Transfersome
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04678505
Drug: MK-3402
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-3402 administered as a single dose of 100 mg IV infusion on the following dosage days:~Panels A to D: Day 1 Panel E: Day 1 in Periods 1 and 2
Trial: NCT06306560
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy IV
Trial: NCT00691795
Drug: Clonidine or fentanyl
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After obtaining consent, the patients will be randomized into two groups using a random allocation table. At the onset of late stage breakthrough pain one arm of patients will receive a mixture of 75 mcg clonidine and 10 mg bupivacaine in 8 ml of volume and the second group will receive 75 mcg fentanyl and 10 mg bupivacaine in 8 ml of volume.
Trial: NCT05331690
Drug: Nepafenac Ophthalmic
RxNorm normalized name: nepafenac ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nepafenac (Nevanac) 3 mg/ml starter the day before surgery
Trial: NCT05331690
Drug: Nepafenac Ophthalmic
RxNorm normalized name: nepafenac ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nepafenac (Nevanac) 3 mg/ml started the day after surgery
Trial: NCT06250959
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HyperCVAD regimen
Trial: NCT06094946
Drug: Fentanyl Citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2.5 micrograms/ml
Trial: NCT01512316
Drug: Lactose pill
RxNorm normalized name: lactose Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one dose, 2hrs prior to fmri
Trial: NCT06313996
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06313996
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05136053
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile solution for infusion
Trial: NCT04883983
Drug: Open Label Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain medication will be prescribed per standard treatment for initial prescription. Pain medication request at followup will be filled with open label placebo. Pain assessment surveys will be used at 2, 6, and 12 week followups.
Trial: NCT05630534
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline is a tetracycline antibiotic routinely used in clinical practice for the treatment of bacterial infection and acne.
Trial: NCT05008939
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received 30% oxygen for 1 hour.
Trial: NCT05556148
Drug: Otrivine Congestion Relief
RxNorm normalized name: olivine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% Nasal Spray (Xylometazoline Hydrochloride)
Trial: NCT05422690
Drug: Induction Chemotherapy Triplet Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 infused on both day 1 and day 8 of a 21-day cycle. Durvalumab 1500 mg will be given on day 1 of each cycle.
Trial: NCT05422690
Drug: Consolidation Doublet Therapy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 given on days 1 and 8 of a 21-day cycle with durvalumab 1500 mg given on day 1 of each cycle for 3-5 additional cycles. For the cycle directly after Y-90, gemcitabine will be kept at a dose of 300 mg/m2 to minimize risk of toxicity.
Trial: NCT06208072
Drug: Eplerenone 25 mg
RxNorm normalized name: eplerenone 25 MG
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eplerenone group will be treated with Eplerenone 25mg twice daily for a total of 8 weeks
Trial: NCT04747275
Drug: Liquid stable levothyroxine (L-T4) Tirosint-SOL
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Investigation of tolerability, palatability, and adherence of liquid levothyroxine (L-T4) for 8 weeks.
Trial: NCT04747275
Drug: Oral tablet levothyroxine (L-T4)
RxNorm normalized name: levothyroxine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigation of tolerability, palatability, and adherence of maintained oral tablet levothyroxine (L-T4) for 8 weeks
Trial: NCT05119413
Drug: New trio de Kligman
RxNorm normalized name: Simparica TRIO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application in addition to the same sunscreen
Trial: NCT05119413
Drug: Trio Kligman
RxNorm normalized name: Simparica TRIO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application in addition to the same sunscreen
Trial: NCT05878691
Drug: GRC 54276
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1a: GRC 54276 QD will be administered orally from Day 1 to Day 21 in a 21-day treatment cycle.~Part 2: GRC 54276 monotherapy therapy will commence after establishment of the MTD and/or RP2D for monotherapy arm.
Trial: NCT06256328
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06256328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose, once daily
Trial: NCT05045274
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Reperfusion therapy: primary percutaneous coronary intervention (PPCI) after DAPT loading (aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally) in the ambulance or emergency department upon diagnosis.~2. Anti-ischemic treatment: DAPT, SC-anticoagulation, beta blockers, statin or others will be individualized according to the patient condition.~3. Anti-failure treatment: Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other diuretics will be added in case of volume overload.
Trial: NCT04643483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous~Subjects will receive placebo in a pre-specified sequence during the Treatment Periods.
Trial: NCT05834062
Drug: Qsymia and lifestyle management therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qsymia will be used at 3.7g mg/23 mg for 12 weeks and then increased to 7.5 mg/46 mg for the remainder of the study. Participants will be offered lifestyle management therapy.
Trial: NCT04768855
Drug: LY3540378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV or SC.
Trial: NCT04768855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV or SC.
Trial: NCT04768855
Drug: LY3540378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT05684718
Drug: BV100 (300 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous solution
Trial: NCT04044898
Drug: ALA 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prepare 10% ALA solution, apply topically to the affected area for 3 hours, single dose
Trial: NCT05020535
Drug: MW189
RxNorm normalized name: Methoxywarfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MW189 (0.25 mg/kg) is administered within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
Trial: NCT04747197
Drug: EYP-1901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection
Trial: NCT06422000
Drug: Probiotic Formula
RxNorm normalized name: Probiotic Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: probiotics sachets supplementation, in the form of lyophilized lactic acid bacteria each Aluminium stick pack contains 100 mg ( Meyer et al., 2020) Probio Tec BB12-Blend 30- IF\* (SANDOZ®.) mixed with 10 ml sterile water and given by Ryle tube once daily until discharge from the unit after clinical and laboratory improvement .
Trial: NCT04996004
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m\^2 by intravenous infusion in 21-day cycles for a maximum of six cycles.
Trial: NCT04300751
Drug: Opioid Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active opioid agonist or placebo, administered orally
Trial: NCT05262517
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT05689203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06520826
Drug: Erythropoiesis Stimulating Agent
RxNorm normalized name: Erythropoiesis stimulating agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care erythropoiesis stimulating agent will be administered to maintain hemoglobin within a target range of 10-11 g/dL.
Trial: NCT05181124
Drug: coadministration of JP-1366 and meloxicam
RxNorm normalized name: bupivacaine and meloxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An open-label, multiple-dosing, fixed sequence, 3-period design
Trial: NCT05181124
Drug: coadministration of JP-1366 and naproxen
RxNorm normalized name: naproxen and diphenhydramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An open-label, multiple-dosing, fixed sequence, 3-period design
Trial: NCT05181124
Drug: single-dosing of JP-1366 in Korean and Caucasian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An open-label, single-dosing, parallel design
Trial: NCT05966948
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline will be intra-articular injected and given two times, on day 1st and 30th day.
Trial: NCT05310032
Drug: HSG4112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral adminstration
Trial: NCT05310032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral adminstration
Trial: NCT06427889
Drug: Canoderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: humectant
Trial: NCT06427889
Drug: Oviderm
RxNorm normalized name: Poviderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: humectant + antimicrobial
Trial: NCT06427889
Drug: Decubal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-humectant
Trial: NCT04356677
Drug: 50 mg/mL Virazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
Trial: NCT04356677
Drug: 100 mg/mL Virazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
Trial: NCT05909293
Drug: Venclexta 100 MG Oral Tablet
RxNorm normalized name: Venclexta 100 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When there is a deficiency of neutrophils, G-CSF treatment may be necessary. The treatment is continued until the absolute neutrophil count (ANC) reaches either \>0.5×109/L and remains at that level for 3 consecutive days, or \>2×109/L. The purpose of G-CSF therapy in this context is to stimulate the production of neutrophils and restore their levels to a sufficient and stable range. This helps to strengthen the immune system and reduce the risk of infections associated with low neutrophil counts.~When experiencing Grade 3-4 thrombocytopenia, subcutaneous injection of IL-11 can be administered as a treatment.~When symptoms of infection occur, aggressive antimicrobial therapy and other supportive treatments should be administered.~All blood products should undergo irradiation when transfused, and all blood products must be filtered before infusion.~If gastrointestinal adverse reactions occur, antiemetic medications can be administered to alleviate symptoms.
Trial: NCT05860582
Drug: [14C]GB491
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 150mg dose of GB491 containing approximately 50 uCi of \[14C\]GB491.
Trial: NCT05594355
Drug: TEBOFORTAN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEBOFORTAN 240 mg is administrated 1 tablet per day
Trial: NCT00081055
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00081055
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05755906
Drug: BD MDI 160 μg BID (320 μg/day)
RxNorm normalized name: immunoglobulin G, human 160 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (BD) metered-dose inhaler (MDI), 160 μg BID (320 μg/day)
Trial: NCT06309030
Drug: Bushen quhan zhiwang decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with 100ml of Bushen quhan zhiwang decoction twice a day for 3 months.
Trial: NCT06309030
Drug: Bushen quhan zhiwang decoction placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with 100ml of Bushen quhan zhiwang decoction placebo twice a day for 3 months.
Trial: NCT05618808
Drug: REGN9933
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of REGN9933 by IV infusion
Trial: NCT05049057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo delivered via subcutaneous injection.
Trial: NCT02974777
Drug: DAPT reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction of standard dose DAPT due to low platelet reactivity
Trial: NCT04680767
Drug: LY3502970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04680767
Drug: [¹⁴C]-LY3502970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05730218
Drug: ONL1204 Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONL1204 Ophthalmic Solution at one of two doses delivered via intravitreal injection
Trial: NCT05850728
Drug: TLC-ART
RxNorm normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Ed-TLC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLC-ART 101 contains lopinavir, ritonavir, and tenofovir in a combination nanoparticle suspension
Trial: NCT05730218
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection is performed by touching the eye surface with a syringe without a needle
Trial: NCT05604287
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participant will receive a oral dose of Placebo.
Trial: NCT05487196
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl belongs to the drug classification of analgesic opioid agonists and is used as the standard of care
Trial: NCT05978206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06104553
Drug: SHR-A1912; R-Chemo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-A1912 combined with R-Chemo: SHR-A1912 + R-Chemo (Rituximab + Chemotherapy) (Phase 1b)
Trial: NCT06104553
Drug: SHR-A1912; R-Chemo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-A1912 combined with R-Chemo: SHR-A1912 (RP2D) + R-Chemo (Rituximab + Chemotherapy) (Phase 2)
Trial: NCT05543707
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 × placebo to match PBI-0451(Pomotrelvir) tablets administered orally BID with food for 5 days (10 total doses)
Trial: NCT05083312
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally disintegrating tablet
Trial: NCT05248880
Drug: AGN-151586
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular Injection
Trial: NCT05248880
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular Injection
Trial: NCT03357419
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will be randomized, at the operation day, to one of two treatment groups:~* group 1: prophylactic antibiotic~* group 2: placebo~  * Sealed envelopes, numbered according to the randomization dose, containing the drug or placebo will be prepared in advance and provided to the patient following randomization.~ * Each patient will be given the randomized drug on admission, 30-60 minutes before the surgery, by the nurses.